Last updated: June 27, 2026
RENOVIST II drug suppliers: Who manufactures, supplies APIs, and provides CDMO services?
No complete, accurate supplier map can be produced for “RENOVIST II” from the information provided. Without the drug’s active ingredient(s), dosage form/strength, marketing authorization holder, and jurisdiction-specific regulatory listing (e.g., FDA/NDC or EMA/MA number), supplier identification and verification against primary records (Orange Book, EMA EPAR, national registers, or published labels) would be incomplete.
What suppliers make RENOVIST II and who is the marketing authorization holder?
A supplier answer requires at least one of the following to identify the correct product record in regulatory databases: the active ingredient name, strength, dosage form, or the marketing authorization holder/manufacturer named on the local label and application file. The term “RENOVIST II” alone does not uniquely identify a single pharmaceutical product, and supplier lists differ by country and by product version (strength, pack size, salt, and manufacturer).
What roles count as “suppliers” for RENOVIST II
- Marketing authorization holder and product label manufacturer
- API manufacturer(s) and intermediate suppliers
- Finished dose manufacturer(s)
- CDMO or tech transfer partner(s) for manufacturing and packaging
- Distributor/wholesaler chain (if you mean “commercial suppliers” rather than manufacturing suppliers)
Which companies supply the API for RENOVIST II?
API supplier identification requires the RENOVIST II active pharmaceutical ingredient (API) and salt form, then cross-checking that API against:
- drug substance sections in regulatory submissions,
- public API manufacture listings where disclosed,
- and company disclosures in labels, inspection records, or filings.
No such API identity is provided.
What finished-dose manufacturers supply RENOVIST II (tablets, injections, creams)?
Finished-dose manufacturer identification depends on the dosage form and strength. Label manufacturing responsibility is usually listed on:
- the product label (country-specific),
- EMA product information,
- or US listing entries tied to NDC and labeler codes.
No dosage form or strength is provided, so a manufacturer list would risk mixing multiple products that share the same brand name.
What CDMOs manufacture RENOVIST II and handle packaging?
CDMO and packaging vendor identification again depends on the confirmed product record and version. CDMO roles can include:
- drug substance manufacturing,
- final drug product manufacturing,
- secondary packaging and labeling,
- stability testing and regulatory release.
Without product identifiers, CDMO attribution cannot be validated.
What is the Orange Book or EMA status of RENOVIST II suppliers?
If the product is FDA-listed, Orange Book data can show:
- NDA/BLA number,
- listed patents,
- and manufacturer/labeler mappings.
If the product is EMA-authorized, EPAR and product information can show:
- MA holder,
- manufacturing sites,
- and batch release arrangements.
No NDA/EMA identifier is provided, so “Orange Book status” and listing-derived supplier mappings cannot be produced.
How do supplier lists differ by country for RENOVIST II?
Brand names frequently map to different legal products across jurisdictions with different:
- MA holders,
- manufacturing sites,
- API sources,
- and labeling requirements.
Without the target market (or regulator record), any supplier list would be non-actionable.
Key Takeaways
- “RENOVIST II” alone is not enough to generate a validated supplier list.
- Supplier identification requires product-specific regulatory identifiers (active ingredient, dosage form/strength, and the applicable marketing authorization holder and/or NDA/EMA number).
FAQs
- How can I confirm the manufacturer of RENOVIST II from the label?
- Does RENOVIST II have different API suppliers by country?
- Where do I find CDMO or packaging site information for a branded drug?
- How do Orange Book or EPAR records map to real-world manufacturing sites?
- What documents list batch release and manufacturing responsibility for brand drugs?
References (APA)
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
- EMA EPAR database. European Medicines Agency.
- FDA NDC Directory (labeler and product identifier mappings). U.S. Food and Drug Administration.
